The Lung Microbiome and Endobronchial Valve Treatment

Launched by AARHUS UNIVERSITY HOSPITAL · Jun 13, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the bacteria in the lungs, known as the microbiome, may affect the risk of infections in patients with emphysema who are receiving a treatment called endobronchial valves (EBV). Emphysema is a serious lung condition that makes it hard to breathe, and while there are treatments available, some patients still struggle with breathing difficulties. The trial aims to understand if certain types of bacteria present in the lungs before and after the EBV procedure are linked to the development of chronic infections.

To be eligible for this trial, participants must be adults aged 65 to 74 who have been diagnosed with chronic obstructive pulmonary disease (COPD) and emphysema, and have been selected for EBV treatment by a team of medical professionals. They will need to provide written consent to join the study. Participants can expect to undergo the EBV procedure, and researchers will monitor their lung bacteria and any potential infections that may arise afterward. This trial is crucial as it may help improve treatment outcomes for patients with emphysema by understanding the role of the lung microbiome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • COPD patients with emphysema selected for EBV treatment by multidiciplinary team, independent of this study.
• • Written informed consent
• Exclusion Criteria:
• • - Intake of oral antibiotics within 1 month before the procedure. Patients receiving preventive long-term treatment with antibiotics can be included.